Hanall Biopharma Co., Ltd. (KRX:009420)

Hanall Biopharma Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 6, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,273,575	1,959,952	2,245,705	902,290	1,077,892	1,919,220
Market Cap Growth	-26.50%	-12.72%	148.89%	-16.29%	-43.84%	3.31%
Enterprise Value	1,261,636	1,934,197	2,185,410	836,710	991,822	1,831,333
Last Close Price	25100.00	38650.00	44300.00	17800.00	21050.00	37500.00
PE Ratio	-	-	640.06	3588.03	121.16	97.10
Forward PE	134.74	117.15	261.09	112.30	65.12	88.99
PS Ratio	9.03	14.11	16.65	8.20	10.61	21.66
PB Ratio	7.99	11.64	12.06	5.36	6.59	10.59
P/TBV Ratio	12.26	11.96	12.18	5.43	6.68	10.74
P/FCF Ratio	158.76	253.93	82.47	40.22	-	-
P/OCF Ratio	134.99	209.40	75.76	35.71	1283.40	2065.25
PEG Ratio	-	19.09	19.09	19.09	19.09	30.69
EV/Sales Ratio	8.95	13.92	16.20	7.61	9.76	20.67
EV/EBITDA Ratio	-	577.20	437.93	183.55	77.34	207.41
EV/EBIT Ratio	-	8392.22	1253.51	555.66	98.21	308.56
EV/FCF Ratio	157.27	250.60	80.26	37.30	-	-
Debt / Equity Ratio	0.01	0.01	0.01	0.01	0.01	0.00
Debt / EBITDA Ratio	0.55	0.43	0.26	0.29	0.10	0.06
Debt / FCF Ratio	0.20	0.19	0.05	0.06	-	-
Asset Turnover	0.68	0.61	0.60	0.53	0.49	0.43
Inventory Turnover	1.86	1.88	2.08	2.11	2.05	2.26
Quick Ratio	1.08	1.29	2.10	2.97	4.35	4.61
Current Ratio	2.66	2.46	3.02	3.92	5.37	5.61
Return on Equity (ROE)	-1.00%	-1.02%	1.98%	0.15%	5.16%	12.29%
Return on Assets (ROA)	-0.08%	0.06%	0.48%	0.46%	3.02%	1.80%
Return on Capital (ROIC)	-0.10%	0.08%	0.61%	0.56%	3.64%	2.30%
Return on Capital Employed (ROCE)	-	0.10%	0.90%	0.80%	5.70%	3.00%
Earnings Yield	-0.13%	-0.09%	0.16%	0.03%	0.83%	1.03%
FCF Yield	0.63%	0.39%	1.21%	2.49%	-0.35%	-0.08%
Buyback Yield / Dilution	2.48%	-0.04%	0.24%	0.76%	-0.05%	-0.00%

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.